3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester:Exports & Compliance White Paper 2026

I. Executive Summary

tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate (CAS 188869-05-8; C10H16BrNO3, MW 278.15) is a Boc-protected α-bromoketone of the piperidin-4-one family whose commercial value rests on one motif: the C3 bromide sits α to the C4 carbonyl and acts as a hard electrophile, giving direct entry into fused aminothiazole-piperidine and 3-aminopiperidine scaffolds used in kinase, protease and CNS discovery programmes. The same feature makes it a bifunctional alkylator with a recognised genotoxicity alert. There is no approved therapeutic indication for this compound; it is supplied exclusively as a Research Use Only intermediate for custom synthesis, not for human or veterinary administration.

Through 2026 the demand pool has separated into two clearly priced tiers. Discovery-phase buyers purchase gram to hundred-gram quantities of RUO-grade material with a 95–97% assay and a routine certificate of analysis, weighting lead time far above documentation depth. Late-preclinical and clinical buyers purchase kilo-scale campaigns requiring ICH Q7 starting-material qualification, a validated chiral assay, an ICH M7 genotoxic-impurity assessment with a compound-specific acceptable intake, and a documented occupational exposure band with an assigned HBEL. Suppliers serving only the first tier lose the account when a programme matures, so documentation capability rather than nameplate capacity is the binding constraint on export growth.

This white paper reviews the route classes that generate the molecule, the impurity and thermal-stability profile that governs its specification, the REACH, CLP, TSCA and FDA-facing instruments that gate entry into the European Union and the United States, and the packaging and cold-chain practices that determine landed cost. It is written for sourcing managers, regulatory officers and CDMO partners who must qualify a supplier against CAS 188869-05-8 and defend that qualification to an auditor. Process discussion is held at the level of legitimate industrial practice: route class, purification strategy, containment and quality systems, with no procedural instruction.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Mechanistically the compound behaves as a textbook α-haloketone: the C3–Br bond is activated by the adjacent ketone toward SN2 displacement, while the carbonyl acts as a condensation partner. The dominant industrial application is Hantzsch-type cyclocondensation with thioamides or thioureas, giving a thiazole annulated onto the piperidine ring and delivering 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives in one dehydrative operation. The product is a pale off-white crystalline solid that darkens as hydrogen bromide is eliminated, and it is moisture- and acid-sensitive because of the Boc carbamate.

• α-Haloketone electrophilicity and competing elimination: Bromine flanked by the C4 ketone undergoes rapid displacement at or below ambient temperature, but a side pathway always competes: base-promoted loss of hydrogen bromide to the 3,4-unsaturated enone, itself a Michael acceptor and a second genotoxic alert. That impurity requires a stability-indicating HPLC method with an explicit limit rather than an area-normalised purity figure.
• Enolisable C3 stereocentre and racemisation risk: C3 carries bromine and hydrogen and is therefore a stereocentre; under acidic or basic conditions the adjacent ketone enolises and the centre racemises. Any chiral specification that omits enantiomeric excess is inadequate: buyers should require a stated ee and the chiral SFC or HPLC method reference.

2.2 Synthesis and Manufacturing Technologies

Commercial supply converges on a few route classes, all beginning from N-Boc-piperidin-4-one, an article of commerce produced at multi-tonne scale in China and India. The engineering challenge is not the bromination itself but suppression of 3,5-dibromination, avoidance of hydrogen-bromide-mediated Boc cleavage during quench, and removal of dehydrohalogenated by-products.

• Kinetic enolate bromination: Deprotonation of N-Boc-piperidin-4-one with a hindered amide base at low temperature, followed by quenching with bromine, N-bromosuccinimide or carbon tetrabromide, installs the C3 bromide under kinetic control. Discipline centres on stoichiometry, addition rate and temperature: excess brominating agent or extended residence at elevated temperature drives the 3,5-dibromo impurity, while residual hydrogen bromide attacks the carbamate.
• Enol-derivative halogenation and alternative variants: Bromination of a pre-formed silyl enol ether or enol acetate, followed by controlled hydrolysis, offers a milder alternative that avoids free hydrogen bromide and reduces Boc loss. Copper(II) bromide on the ketone is a documented variant. Crystallisation is normally the sole purification, so polymorph and ICH Q3C residual-solvent control determine lot-to-lot reproducibility.

2.3 Core Application Matrix

• Fused aminothiazole scaffolds: Condensation with thioamides, thioureas or amidines furnishes tetrahydrothiazolo[5,4-c]pyridine and related bicyclic amines, privileged fragments in kinase and protease inhibitor design. The Boc group survives cyclocondensation, so the ring nitrogen can be unmasked late for amide coupling or reductive amination.
• Substituted 3-aminopiperidines: Displacement of bromide with azide, phthalimide or a protected amine, followed by stereoselective ketone reduction, gives 3-amino-4-hydroxypiperidine motifs found in dipeptidyl peptidase and serine protease inhibitor families — the highest-volume downstream use.
• Reference standards and impurity synthesis: Because the compound is both a building block and a potential genotoxic impurity carried into downstream APIs, campaigns routinely buy a second, fully characterised lot as a reference standard to support method validation and spike-and-purge studies.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for CAS 188869-05-8 tracks discovery spending on sp3-rich nitrogen heterocycles rather than any single commercial launch. Three shifts define 2026: the migration of medicinal chemistry away from flat heteroaromatics has raised per-programme consumption of brominated piperidones; buyers increasingly outsource the hazardous bromination step to specialist CDMOs, converting captive capacity into traded volume; and enquiry converts to orders only when the supplier can present a defensible purge argument. Documented kilo-scale material remains the tightest segment of the market.

3.2 Capacity Distribution and Export Flows

Nameplate capacity is abundant; qualified capacity is not. Chinese producers in Shandong, Jiangsu and Zhejiang supply most catalogued lots from shared multipurpose plants with dedicated bromination suites. Indian CDMOs in Hyderabad, Bengaluru and Ahmedabad compete on documented GMP campaigns and English-language dossiers rather than on price. EU and US custom houses hold smaller capacity but win on OEB containment and ICH Q7 packages. Flows run east to west, with repackaging and analytical release activity concentrated in Singapore and the Netherlands.

3.3 Market Bifurcation and Pricing Dynamics

The market bifurcates sharply. Catalogued RUO material at 95–97% assay trades on a spot basis with thin margins and high substitutability between brokers. Documented material — chiral assay, validated genotoxic-impurity method, ICH Q7 documentation, thermal-stability data and validated cold chain — commands multiples of that price under annual agreements with adjustment clauses tied to bromine, solvent and energy costs. Buyers specifying only an assay number invite substitution of under-documented lots.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Four themes decide whether a shipment clears its destination: the genotoxic-impurity argument, the EU registration position, the US inventory position, and the occupational-exposure and containment evidence downstream pharmaceutical customers audit. None is satisfied by a generic certificate of analysis, and all surface during supplier qualification rather than at customs.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration and intermediate status: A non-EU manufacturer cannot register directly. Importers above one tonne per year must hold or be covered by a registration, appoint an Only Representative, or demonstrate handling under strictly controlled conditions as a registered intermediate under the REACH intermediate provisions. Buyers should obtain a written REACH statement and registration strategy before contracting.
• CLP self-classification and the ICH M7 overlay: No Annex VI harmonised classification exists for this CAS, so suppliers self-classify and must notify the C&L Inventory; α-haloketone chemistry normally supports acute toxicity and skin and serious eye irritation or corrosion. Separately, pharmaceutical customers apply ICH M7: the structural alert places the compound in Class 3, requiring control to the threshold of toxicological concern or to a compound-specific PDE derived from a bacterial reverse mutation assay or defensible read-across.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory, exemptions and import certification: Substances absent from the TSCA Chemical Substance Inventory require a premanufacture notice or a valid exemption before commercial import. Material supporting research and development may qualify for the TSCA R&D exemption, which carries labelling, recordkeeping and, above defined volume thresholds, notification duties. Importers should require a written TSCA compliance statement naming the listing or exemption relied upon.
• FDA-facing quality expectations for the intermediate: An intermediate is not a drug substance, yet reviewers expect ICH Q11 justification of the starting-material designation, ICH Q7 site control, ICH Q3C residual-solvent limits and an ICH Q3D elemental-impurity assessment. Where the α-bromoketone is introduced late in a synthesis, the purge argument for the parent and for its enone by-product will be scrutinised; DMF support materially shortens qualification.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

ESG scrutiny of halogenated intermediates has intensified alongside the European chemicals sustainability agenda. Material issues here are bromination mass efficiency, solvent and bromide waste load, the energy burden of sub-ambient processing and cold storage, and the credibility of emissions and waste-chain documentation.

5.1 Carbon Footprint and Circular Economy

Dominant contributors are low-temperature enolate chemistry, solvent recovery by distillation and continuous refrigeration through warehousing and transport. Suppliers running semi-continuous bromination with high solvent recovery and high-efficiency refrigeration document materially lower kg CO2e per kg than batch operators venting solvent and incinerating mother liquors. Buyers feeding supplier factors into Scope 3 category 1 should request ISO 14001 or ISO 50001 certification and a product-level footprint to ISO 14067 or the GHG Protocol Product Standard.

5.2 Sustainable Sourcing and Traceability

Expectations now extend past the immediate supplier to bromine and solvent provenance and to waste-treatment chain of custody. Responsible suppliers maintain batch genealogy linking each lot to raw-material certificates, document treatment of bromination by-products and bromide brine, and operate a code of conduct audited under ISO 9001. Because REACH and customer questionnaires both ask for upstream site identification, brokers who cannot name the plant are progressively disqualified.

VI. Supply Chain Resilience and Export Logistics

Logistics for this CAS are governed by thermal instability rather than transport classification. The α-bromoketone eliminates hydrogen bromide or disproportionates on prolonged exposure to warmth or base, and the carbamate is cleaved by acid; both are invisible on a release certificate. Time-temperature budget is therefore the controlling specification for the whole lane.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture, oxygen and acid exclusion: Product belongs in amber glass or high-barrier lined containers closed under nitrogen with minimised headspace. Closures and liners must be compatible with brominated organics and free of acidic or basic residues, since either catalyses degradation. Certificates should report Karl Fischer water and headspace GC residual solvents against ICH Q3C limits.
• Temperature-controlled packaging and lane qualification: Gel-refrigerant packs for 2–8 °C or dry ice for frozen shipment must be qualified against the lane's worst-case ambient profile with a documented hold-time study. Calibrated data loggers should accompany every qualifying shipment. Because dry ice is itself a Class 9 dangerous good, its use requires correct marking, vented packaging and explicit carrier acceptance.

6.2 Dangerous Goods Identification and Transit Protocols

Classification is dossier-dependent: many suppliers ship as a non-regulated solid on available data, while others apply a Class 8 corrosive solid, organic, n.o.s. entry where corrosion data support it. Buyers should require the classification rationale and SDS section 14 data and confirm the applicable ADR, IMDG and IATA provisions rather than accepting a courier default. Protocol: refrigerated or frozen transport, no consolidation with acids or amines, avoidance of summer lanes without reefer capability, and a written excursion procedure defining re-test and rejection.

VII. Enterprise Global Expansion Strategy Guide

For exporters, durable advantage comes from converting a commodity bromination into a documented, auditable service. Three actions deliver most of the available value.

1. Build a genotoxic-impurity dossier, not merely a certificate: Commission a bacterial reverse mutation assay or prepare a defensible read-across, derive a compound-specific permitted daily exposure or apply the threshold of toxicological concern, and publish a purge-factor study across a representative quench, extraction and crystallisation sequence. This converts a disqualifying structural alert into a managed control point.
2. Offer a two-tier product architecture: Define a standard RUO grade and a qualified GMP-compatible grade with explicit differences in assay, enantiomeric excess, individual impurity limits, documentation set and containment. Customers then match spend to programme stage, and the supplier captures the value uplift at phase transition instead of losing the account to a Western CDMO.
3. Invest in containment and cold-chain evidence: Documented OEB assignment, dedicated or campaign-cleaned bromination suites, closed sampling and validated refrigerated packaging with lane qualification are visible, auditable assets. Pair them with ISO 9001 and ISO 14001 certification, an Only Representative or importer-support service for EU buyers, a written TSCA status statement for US buyers, and know-your-customer screening on RUO shipments.

VIII. Conclusion

tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate is a small-volume, high-scrutiny intermediate whose trajectory is set by documentation depth rather than synthesis difficulty. Route chemistry is well understood and capacity is plentiful; what is scarce is the combination of stereochemical control, genotoxic-impurity reasoning, thermal-stability data and cold-chain discipline that lets a customer defend the material inside a regulatory filing. Suppliers treating those as product features will take share through 2026.

Buyers should specify the molecule in full — CAS 188869-05-8, assay, enantiomeric excess where applicable, water content, residual solvent, individual limits for the enone and 3,5-dibromo impurities, and storage temperature — and audit thermal-stability, containment and purge data before the first order. The compound has no approved therapeutic indication and is supplied for research and development use only; its value lies entirely in what a competent, containment-capable CDMO partner can build from it under controlled, documented conditions.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 3-Bromo-4-oxo-piperidine-1-carboxylic acid tert-butyl ester supply chain:

• China — Shandong, Jiangsu and Zhejiang production base: Chinese producers supply most catalogued global volume from shared multipurpose plants with dedicated bromination capability, offering gram to kilogram quantities on short lead times at aggressive prices. Differentiation is widening: leading houses now offer chiral assay capability, ICH Q7-style documentation and validated cold-chain packing.
• India — Hyderabad, Bengaluru and Ahmedabad CDMO cluster: Indian CDMOs position this CAS as a custom-synthesis and scale-up offering rather than a catalogue item, bundling route scouting, analytical method development and validation. English-language regulatory dossiers, DMF support and established relationships with US and EU pharmaceutical customers are the principal advantages.
• European Union and North America — containment-capable specialist houses: EU and US custom-synthesis houses hold limited nameplate capacity but lead on OEB-classified containment, ICH Q7 and Q11 starting-material packages, REACH and TSCA compliance support, and proximity to clinical supply chains. They are selected for late-stage GMP campaigns and reference-standard programmes where auditability outweighs unit cost.